招待講演3［Clinical Trial Network Session］

[SK3-1] Synthesis and Imaging of Neuroendocrine Tumors Using Ga-68 Labeled Somatostatin Analogs

^○David W. Dick (Radiochemistry, Department of Radiology, University of Iowa, USA)

Dr. David W. Dick is a Clinical Assistant Professor and Chief of Radionuclide Production & Clinical PET Radiochemistry in the Department of Radiology at the University of Iowa. Prior to coming to Iowa he was the Head of Cyclotron Physics in the Department of Radiology at Stanford University. He received his BS in physics from Western Washington University, and his MS and Ph.D. in medical physics from the University of Wisconsin-Madison. Dr. Dick is the chair of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Clinical Trials Network Radiopharmaceutical Manufacturers Committee, Vice President-Elect of the SNMMI Radiopharmaceutical Sciences Council, and a board member of the SNMMI PET Center of Excellence.
Dr. Dick has 14 peer-reviewed publications, 1 book chapter, and given 18 invited lectures.
Dr. Dick has a broad skill set, but specializes in the translation of radiotracers to the clinic and regulatory affairs related to radiopharmaceuticals. His expertise was confirmed by being selected for an International Atomic Energy Agency (IAEA) panel for recommendations for introduction radiopharmaceuticals for clinical use. This panel group authored the IAEA publication "Good Practice for Introducing Radiopharmaceuticals for Clinical Use." Dr. Dick's facility has produced hundreds of doses of Ga-68 DOTATOC for clinical research use, impacting the management of hundreds of patients with neuroendocrine tumors, and he is considered one of the authorities with respect to clinical Ga-68 radiochemistry within the United States.